Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Jean-François Rossignol, Jean-François Rossignol
Abstract
Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits in vitro activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting expression of the viral N protein. Nitazoxanide also suppresses production of pro-inflammatory cytokines in peripheral blood mononuclear cells and suppresses interleukin 6 production in mice. Having been used extensively in clinical trials and in post-marketing experience, nitazoxanide is an attractive drug candidate for treatment of Middle East respiratory syndrome. Future research should include in vitro mechanism studies, animal models of MERS-CoV infection, clinical trials, including dose-ranging trials, and evaluation of combination therapy with other potential MERS-CoV antivirals.
Keywords: Coronavirus; MERS-CoV; Nitazoxanide; Treatment.
Copyright © 2016 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved.
References
- Zumla A., Azhar E.I., Arabi Y., Alotaibi B., Rao M., McCloskey B. Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections. Int J Infect Dis. 2015;40:71–74.
- Rossignol J.F. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014;110:94–103.
- Rossignol J.F., La Frazia S., Chiappa L., Ciucci A., Santoro M.G. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at post-translational level. J Biol Chem. 2009;284:29798–29808.
- Belardo G., Cenciarelli O., La Frazia S., Rossignol J.F., Santoro M.G. The novel anti-influenza nitazoxanide acts in synergism with neuraminidase inhibitors. Antimicrob Agents Chemother. 2015;59:1061–1069.
- Lam K.K.Y., Zheng X., Forestieri R., Balgi A.D., Nodwell M., Volett S. Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis. PLoS Pathog. 2012;8:e1002691.
- Romark Laboratories . 2007. L.C. Alinia® (nitazoxanide) prescribing information.
- Cao J., Forrest J.C., Zhang X. A screen of the NIH collection small molecule library identifies potential coronavirus. Antiviral Res. 2015;114:1–10.
- Hong S.K., Kim H.G., Chong C.S., Choi I.S., Lee J.B., Park S.Y. Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice. Int Immunopharmacol. 2012;13:23–27.
- Haffizulla J., Hartman A., Hoppers M., Resnick H., Samudrala S., Ginocchio C. A randomized, double-blind, placebo controlled clinical trial of nitazoxanide in adults and adolescents with acute uncomplicated influenza. Lancet Infect Dis. 2014;14:609–618.
Source: PubMed